<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600376</url>
  </required_header>
  <id_info>
    <org_study_id>EGL-4104-C-1801</org_study_id>
    <nct_id>NCT03600376</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS</brief_title>
  <official_title>Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eagle Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eagle Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat
      stroke (EHS) compared to current Standard of Care (SOC) for EHS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following triage and primary assessment in the emergency medical facility, subjects will be
      randomized to 1 of 2 treatment arms, SOC plus Ryanodex or SOC only. Subjects will be dosed
      and followed for up to 6 hours post-randomization. Current SOC is limited to body cooling and
      supportive measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2018</start_date>
  <completion_date type="Actual">August 14, 2019</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow Coma Score (GCS) greater than or equal to 13</measure>
    <time_frame>90 minutes post-randomization</time_frame>
    <description>The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Score (GCS) greater than or equal to 13 at planned time points</measure>
    <time_frame>Up to 6 hours post-randomization</time_frame>
    <description>The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Exertional Heat Stroke</condition>
  <arm_group>
    <arm_group_label>Ryanodex and Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care only (SOC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care treatment will consist of the immediate start of cooling measures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ryanodex and Standard of Care</intervention_name>
    <description>Ryanodex to be administered as a rapid IV push</description>
    <arm_group_label>Ryanodex and Standard of Care</arm_group_label>
    <other_name>Ryanodex and SOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Body cooling measures and supportive measures</description>
    <arm_group_label>Standard of Care only (SOC)</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Core body temperature of greater than or equal to 40.0 degrees C (104
        degrees F); recent history of exertional activity; GCS score less than 13; tachycardia -

        Exclusion Criteria: clinical severe infection; hyperthermia secondary to another condition;
        endotracheal intubation;; sedative drugs administered prior to or at time of study entry;
        likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of
        myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant
        or prior use of calcium channel blockers.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hepner</last_name>
    <role>Study Director</role>
    <affiliation>Eagle Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Hospital</name>
      <address>
        <city>Mecca</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mina al Jisr Hospital</name>
      <address>
        <city>Mina</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mina Al-Shari Al-Jadeed Hospital</name>
      <address>
        <city>Mina</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mina Al-Wadi Hospital</name>
      <address>
        <city>Mina</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heat Stroke</mesh_term>
    <mesh_term>Sunstroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dantrolene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

